An international interpretation community includes the Evidence-based Network for the Interpretation of Germline Mutant Alleles (ENIGMA) consortium [5], established to investigate the clinical significance of variants in breast−ovarian cancer predisposition genes, and which is recognized by Clinical Genome Resource (ClinGen) as an expert panel for interpretation of BRCA1 and BRCA2 variants. Here, BRCA1 is linked to cancer.